Article

A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma

2022-03-22

Abstract excerpt

<h4>Background: </h4> Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor-T cell (CAR T) therapy shows remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). C-CAR088, a novel second-generation humanized anti-BCMA CAR T cell therapy, was developed. <h4>Methods: </h4> This phase I dose-escalation and expansion study assessed the safety and efficacy of three dosages of C-CAR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: def5fbe4-d6c1-5827-a334-3ad72310760e
DOI: 10.21203/rs.3.rs-1468511/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myelomaDOI 10.21203/rs.3.rs-1468511/v1Read

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myelomaSemantic proximity Read

Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responsesSemantic proximity Read

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsSemantic proximity Read

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaSemantic proximity Read

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaSemantic proximity Read